文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

氢化可的松治疗极早产儿早期支气管肺发育不良:随机对照试验研究方案

Hydrocortisone to treat early bronchopulmonary dysplasia in very preterm infants: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-09-03

支气管肺发育不良(BPD)是极早产儿常见并发症且缺乏有效治疗。本方案为多中心双盲随机对照试验,评估低剂量氢化可的松治疗生后28天诊断的早期BPD的疗效与安全性,主要结局为矫正胎龄36周时无中重度BPD存活。

要点

  • 低剂量氢化可的松方案为0.5 mg/kg每日两次用7天,随后0.5 mg/kg每日一次用3天。
  • 主要结局为矫正胎龄36周时无中重度BPD存活。
  • 对照组给予等体积安慰剂,在常规治疗基础上不加干预。

核心结论

  • 本试验将确定低剂量氢化可的松与安慰剂相比,能否减少极早产儿早期BPD在矫正胎龄36周时的中重度BPD。

研究设计与样本

  • 多中心双盲随机对照试验,纳入生后28天诊断的早期BPD极早产儿,随机分为氢化可的松组或对照组。
  • 氢化可的松组给予0.5 mg/kg每日两次用7天,随后0.5 mg/kg每日一次用3天;对照组给予等体积安慰剂。
  • 主要结局为矫正胎龄36周时无中重度BPD存活,次要结局包括对生长、代谢、神经发育及其他可能并发症的短期和长期影响。

关键数值与推荐

  • 氢化可的松剂量:0.5 mg/kg每日两次用7天,随后0.5 mg/kg每日一次用3天。
  • 主要结局:矫正胎龄36周时无中重度BPD存活。
  • 试验注册:中国临床试验注册中心ChiCTR1900021854,注册日期2019年3月13日。

临床怎么用

  • 目前尚无研究报道氢化可的松治疗生后28天诊断的早期BPD的疗效与安全性,本试验结果可为该人群用药提供依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bronchopulmonary dysplasia (BPD) is still a common complication in very premature infants. At present, there is no effective treatment for BPD. Glucocorticoids are drugs commonly used to prevent or treat BPD before and after birth. In very premature infants with high risk factors for BPD, early use of dexamethasone can reduce the rate of death and/or BPD but may cause long-term adverse neurodevelopmental outcomes. Hydrocortisone (HC), as an alternative drug to dexamethasone, has been increasingly used to prevent BPD. However, no study has reported the efficacy and safety of HC to treat early BPD diagnosed at postnatal day (PND) 28. METHODS: This study protocol is for a multicenter double-blind randomized controlled trial of low-dose HC in the treatment of early BPD. Early BPD infants will be randomly assigned to the HC treatment group or control group. Infants in the HC group will receive 0.5 mg/kg HC twice a day for 7 days and then 0.5 mg/kg HC once a day for 3 days. The control group will be given the same volume of placebo and no intervention on the basis of routine treatment. The primary outcome is survival without moderate or severe BPD at 36 weeks postmenstrual age. Secondary outcomes are the short- and long-term effects on growth, metabolism, neurodevelopment, and other possible complications. DISCUSSION: This trial will determine the efficacy and safety of low-dose HC administration compared to placebo for the reduction of moderate or severe BPD at 36 weeks postmenstrual age in very preterm infants with early BPD. TRIAL REGISTRATION: China Clinical Trial Registration Center ChiCTR1900021854 . Registered on 13 March 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. He Y, Zhang Y, Gao S, et al. Hydrocortisone to treat early bronchopulmonary dysplasia in very preterm infants: study protocol for a randomized controlled trial. Trials. 2020. PMID: 32883333. doi:10.1186/s13063-020-04698-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。